Contents of this article
Peptides operate at the crossroads of endocrine, neuroendocrine, and paracrine signaling, coordinating energy balance, nutrient metabolism, and tissue-specific metabolic responses. Because of their roles in glucose regulation, lipid handling, appetite, and energy expenditure, peptide hormones and neuropeptides constitute key regulators of whole-body metabolic homeostasis and attractive targets for therapeutic intervention in obesity, type 2 diabetes (T2D), NAFLD and other metabolic disorders.
Many of these peptides are produced as larger precursors (preprohormones) and are proteolytically converted into their bioactive forms, which then exert effects primarily through G-protein-coupled receptors (GPCRs), triggering intracellular signaling cascades such as cAMP or IP₃/Ca²⁺ pathways.
Peptides in metabolic physiology
Central (hypothalamic/neuro-endocrine) Peptides
The central nervous system notably the hypothalamus integrates peripheral signals (hormones, nutrients, neural signals) to regulate appetite, satiety, energy expenditure, and autonomic output. Key neuronal populations include orexigenic Neuropeptide Y (NPY) / Agouti-related peptide (AgRP) neurons that stimulate food intake, and anorexigenic pro-opiomelanocortin (POMC) neurons that produce α-MSH, suppressing feeding. Peripheral hormones such as Leptin, Insulin, Ghrelin, PYY, CCK and gut-derived GLP-1 relay information about energy stores and recent food intake, modulating these central circuits. Appetite and energy balance regulation thus arises from a complex interplay of peptide signals, neurotransmitters, and systemic hormones.
Pancreatic, gut and adipose-derived Peptides
Multiple peptides secreted by the pancreas, gut and adipose tissue coordinate post-prandial metabolism and long-term energy balance:
- Insulin: promotes uptake of glucose and storage as glycogen or fat; central to glucose homeostasis.
- Glucagon: stimulates hepatic glucose production and mobilizes energy stores under fasting conditions.
- Amylin: co-secreted with insulin, slows gastric emptying and blunts postprandial glucose spikes; helps moderate appetite.
- Somatostatin: regulates secretion of several hormones including insulin and glucagon, modulating the balance between nutrient storage and mobilization.
- Adipokines (e.g. adiponectin): secreted by adipose tissue; adiponectin promotes fatty-acid oxidation, improves insulin sensitivity, and helps maintain healthy lipid and glucose metabolism, mitigating ectopic fat deposition.
- Ghrelin: primarily secreted from the stomach; especially in its acylated form, ghrelin stimulates appetite and, under certain conditions, may promote lipogenesis though its net metabolic effects vary depending on nutritional status, tissue context, and receptor distribution.
Because each peptide acts in a specific context (fasting vs. feeding, tissue type, energy state), metabolic regulation is highly dynamic and responsive.
Peptide-based therapeutics for metabolic diseases
GLP-1 receptor agonists & related therapies
Long-acting gut hormone analogues, particularly GLP-1 receptor agonists (GLP-1 RAs), have become a cornerstone in managing type 2 diabetes (T2D) and obesity. These agents enhance glucose-dependent insulin secretion, suppress inappropriate glucagon release, slow gastric emptying, and promote satiety, leading to clinically significant weight loss and improved glycemic control. Their efficacy and cardiovascular benefits are well-established through extensive randomized clinical trials and real-world evidence.
Dual/Triple receptor-agonist Peptides
The field has rapidly evolved beyond single-hormone mimics. Targeting complementary metabolic pathways simultaneously has proven to enhance efficacy beyond that of selective GLP-1 RAs like Semaglutide, leading to the development of multi-agonist peptides.
- Dual Agonists: Agents co-activating the GIP and GLP-1 receptors (e.g., Tirzepatide) have demonstrated superior weight loss and glycemic improvement compared to selective GLP-1 RAs in pivotal trials, establishing a new efficacy benchmark and validating the multi-agonist approach.
- Triple Agonists: The most advanced in this novel class is Retatrutide, a single peptide that is a potent agonist for the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
Retatrutide represents a significant frontier in pharmacotherapy for obesity and metabolic disease. Its mechanism is designed to harness the complementary effects of three key metabolic hormones:
- GLP-1 receptor agonism for satiety, glycemic control, and weight loss.
- GIP receptor agonism to enhance metabolic efficiency and potentiate the effects of GLP-1, with emerging evidence suggesting it may mitigate gastrointestinal side effects.
- Glucagon receptor agonism to increase energy expenditure and potently reduce liver fat, targeting key drivers of hepatic and metabolic health.
Amylin analogs and combination therapies
Analogues of amylin (a hormone co-secreted with insulin) reduce appetite and support weight reduction. When combined with GLP-1 receptor agonists, amylin analogs may yield additive or synergistic effects on weight loss and metabolic control. Ongoing larger clinical trials are exploring their long-term efficacy and safety, making them promising candidates for combination peptide therapy in metabolic disease.
Advances in Peptide delivery for the metabolic system
Because peptides are subject to proteolytic degradation and often have poor oral bioavailability, delivering them effectively has been a challenge. Recent advances such as the development of oral formulations using permeation enhancers, chemical modifications (lipidation, albumin-binding), depot (long-acting) injections, and extended-release formulations have significantly improved their pharmacokinetics and patient convenience. Research is also underway into next-generation delivery systems (e.g. nanoparticle-based platforms, targeted delivery) to expand tissue specificity and minimize side effects, though many of these remain at preclinical stages.
Challenges, safety, and therapeutic limitations
While metabolic peptides are powerful therapeutic tools, several challenges remain:
- Adverse effects notably gastrointestinal symptoms (nausea, vomiting) are common, especially during dose escalation.
- Long-term safety and tolerability: novel dual-/triple-agonists lack extended safety data; the durability of benefits after discontinuation is uncertain.
- Cost and access: peptide therapies may be expensive, and long-term treatment may be required to maintain benefits.
- Disease-specific outcomes: for conditions like NAFLD/NASH, while weight loss improves liver fat, direct evidence that peptide therapies reverse liver fibrosis, inflammation, or long-term hepatic outcomes remains limited.
Future directions & research
Long-term randomized controlled trials are needed to evaluate not only changes in weight and glycemic control but also “hard” clinical outcomes such as cardiovascular events, renal outcomes, and liver histological improvements in conditions like NAFLD and NASH. The development of personalized peptide therapies is an important future direction, with treatments tailored to an individual’s metabolic profile, genetic background, comorbidities, and potentially even their microbiome composition. Advances in targeted delivery mechanisms will also be essential, as more precise delivery technologies can reduce off-target effects and enhance tissue-specific efficacy of metabolic peptides.
Another significant area of growth lies in combination approaches pairing peptides with lifestyle modification, combining multiple peptide agonists, or integrating peptides with other drug classes to maximize therapeutic benefit while minimizing side effects or tolerance.
Peptides occupy a central and versatile role in metabolic regulation: from neuro-endocrine control of appetite to peripheral modulation of glucose and lipid metabolism, they orchestrate complex, context-dependent physiological responses. The translation of this biology into peptide-based therapies from foundational GLP-1 receptor agonists like Semaglutide, to multi-target agents like Tirzepatide and Retatrutide, and combination approaches with amylin analogues marks a paradigm shift in treating metabolic diseases such as obesity and type 2 diabetes. Crucially, their efficacy is reflected not only in weight loss and glycemic control but also in the systemic restoration of metabolic health, as evidenced by biomarkers like the rise in beneficial adipokines such as adiponectin.
Research sources:
Frank Hauser, Thomas L. Koch, and Cornelis J. P. Grimmelikhuijzen. Published in Frontiers in Endocrinology 2022 | DOI: 10.3389/fendo.2022.973862
Integrative neurocircuits that control metabolism and food intake
Jens C. Brüning and Henning Fenselau. Published in Science Neuroscience 2023 | DOI: 10.1126/science.abl7398
Peptide Hormone Expression and Precursor Processing
J.F. Rehfeld, L. Bardram, P. Cantor,J. Cerman, L. Hilsted, A. H. Johnsen, N. Mogensen, and L. Osdum. Published in Taylor and Francis Online Acta Oncologica 2009 | DOI: 10.3109/02841868909111199
Adiponectin/adiponectin receptor in disease and aging
Masato Iwabu, Miki Okada-Iwabu, Toshimasa Yamauchi, and Takashi Kadowaki. Published in Nature npj Aging and Mechanisms of Disease 2015 | DOI: 10.1038/npjamd.2015.13
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P.H. Wilding, D.M., Rachel L. Batterham, M.B., B.S., Ph.D., Salvatore Calanna, Ph.D., Melanie Davies, M.D., Luc F. Van Gaal, M.D., Ph.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Barbara M. McGowan, M.D., Ph.D., Julio Rosenstock, M.D., Marie T.D. Tran, M.D., Ph.D., Thomas A. Wadden, Ph.D., Sean Wharton, M.D., Pharm.D., Koutaro Yokote, M.D., Ph.D., Niels Zeuthen, M.Sc., and Robert F. Kushner, M.D. for the STEP 1 Study Group. Published in The New England Journal of Medicine 2021 | DOI: 10.1056/NEJMoa2032183
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D., Nadia N. Ahmad, M.D., M.P.H., Sean Wharton, M.D., Pharm.D., Lisa Connery, M.D., Breno Alves, M.D., Arihiro Kiyosue, M.D., Ph.D., Shuyu Zhang, M.S., Bing Liu, Ph.D., Mathijs C. Bunck, M.D., Ph.D., and Adam Stefanski, M.D., Ph.D. for the SURMOUNT-1 Investigators. Published in The New England Journal of Medicine 2022 | DOI: 10.1056/NEJMoa2206038
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
W. Timothy Garvey, M.D., Matthias Blüher, M.D., Cynthia Karenina Osorto Contreras, M.D., Melanie J. Davies, M.D., Eva Winning Lehmann, M.D., Ph.D., Kirsi H. Pietiläinen, M.D., Ph.D., Domenica Rubino, M.D., Paolo Sbraccia, M.D., Ph.D., Thomas Wadden, Ph.D., Niels Zeuthen, M.Sc., and John P.H. Wilding, D.M. for the REDEFINE 1 Study Group. Published in The New England Journal of Medicine 2025 | DOI: 10.1056/NEJMoa2502081
Vanita R. Aroda, Lawrence Blonde, and Richard E. Pratley. Published in Springer Nature Reviews in Endocrine and Metabolic Disorders 2022 DOI: 10.1007/s11154-022-09735-8
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Louis J. Aronne, M.D., Deborah Bade Horn, D.O., Carel W. le Roux, M.D., Ph.D., Wayne Ho, M.D., Beverly L. Falcon, Ph.D., Elisa Gomez Valderas, M.Sc., Sagar Das, M.Sc., Clare J. Lee, M.D., M.H.S., Leonard C. Glass, M.D., Cagri Senyucel, M.D., Ph.D., and Julia P. Dunn, M.D. for the SURMOUNT-5 Trial Investigators. Published in The New England Journal of Medicine 2025 | DOI: 10.1056/NEJMoa2416394
Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial